Biopharmaceutical News and Research

RSS

ViroPharma receives European Centralized Marketing Authorization for Cinryze for treatment of HAE

ViroPharma Incorporated today announced that the European Commission has granted ViroPharma Centralized Marketing Authorization for Cinryze (C1 inhibitor [human]) in adults and adolescents with hereditary angioedema (HAE) for routine prevention, pre-procedure prevention and acute treatment of angioedema attacks.

16 Jun 2011

Saint-Gobain introduces new C-Flex ULTRA TPE pump tubing for biopharmaceutical applications

Saint-Gobain Performance Plastics has expanded its line of thermoplastic elastomer (TPE) tubing with the addition of new C-Flex® ULTRA pump tubing, a product designed specifically to perform in demanding biopharmaceutical applications such as pumping, single-use assemblies, process filling and sampling.

15 Jun 2011

immatics initiates IMA901 Phase III trial in renal cell carcinoma

igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma.

15 Jun 2011

Sangart commences MP4OX Phase 2b study in acute traumatic injury

Sangart, Inc., a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic tissues through targeted oxygen and other gas delivery, today announced the initiation of a Phase 2b study designed to evaluate the efficacy and safety of MP4OX treatment plus standard of care in severely injured trauma patients with lactic acidosis due to hemorrhagic shock.

15 Jun 2011

Morimatsu acquires Pharmadule

Morimatsu Industry Co., Ltd., the privately owned Japanese pioneer of tank technology, has acquired Pharmadule AB of Sweden, the world leader of modular manufacturing facilities for the pharmaceutical & biopharmaceutical industries.

14 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

Saint-Gobain Performance Plastics redesigns standard laboratory carboy

Saint-Gobain Performance Plastics has redesigned the standard laboratory carboy, adding a variety of ergonomic features that improve ease of use in advanced biopharmaceutical fluid handling and solution storage applications. These improvements are based on extensive input from professionals who work in laboratory and pharmaceutical environments.

13 Jun 2011

Trimeris, Synageva enter definitive merger agreement

Synageva BioPharma Corp., a privately held biopharmaceutical company developing therapeutic products for rare disorders, and Trimeris, Inc., announced today that they have entered into a definitive agreement under which Synageva will merge with Trimeris in an all-stock transaction.

13 Jun 2011

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced the results of a phase II clinical trial showing that patients who received four doses of its ToleroMune cat allergy vaccine over a 12-week period maintained a statistically significant reduction in symptoms one year later.

13 Jun 2011

Hanwha, Merck partner to develop and commercialize HD203

Merck, known as MSD outside the United States and Canada, and Hanwha Chemical Corporation today announced that they have entered into an exclusive global agreement to develop and commercialize a candidate biosimilar form of Enbrel.

13 Jun 2011

Ambit Biosciences raises $30 million through Series D-2 equity financing

Ambit Biosciences (Ambit), an emerging biopharmaceutical company engaged in the development of kinase inhibitors for the treatment of cancer and other conditions, today announced that it has completed a Series D-2 round of equity financing, raising $30 million in new capital.

10 Jun 2011

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Repligen Corporation today reported results for the fourth quarter and fiscal year 2011, ended March 31, 2011.

9 Jun 2011

Grifols officially merges with Talecris Biotherapeutics

Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain, today announced that it has officially begun to merge its operations with Talecris Biotherapeutics in order to function as one company, following its acquisition of Talecris on June 1.

8 Jun 2011

Shire Canada receives expanded indication for MEZAVANT for treatment of ulcerative colitis

Shire Canada Inc., a division of Shire plc, the global specialty biopharmaceutical company, is proud to announce that MEZAVANT® (mesalamine delayed and extended release tablets), the first and only once-daily mesalamine indicated for the induction of clinical and endoscopic remission in patients with mild-to-moderate, active ulcerative colitis (UC), has received an expanded indication to include maintenance of clinical and endoscopic remission (mucosal healing) in patients with ulcerative colitis.

7 Jun 2011

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline.

7 Jun 2011

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

The PATH Malaria Vaccine Initiative (MVI) announced today that it has entered into a collaboration with Dutch biopharmaceutical company Crucell N.V. and GlaxoSmithKline (GSK). This collaboration is aimed at developing a second-generation vaccine against malaria—a deadly disease that kills close to 800,000 people annually, most of them young children under age five in Africa. MVI drives the development of malaria vaccines by joining its scientific, managerial, and field expertise with companies, universities, and governments to test potential malaria vaccines and invest in those with the most promise.

6 Jun 2011

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

TRION Pharma GmbH has announced that the results from two different studies demonstrate catumaxomab’s capacity to activate the immune system in a way that can otherwise only be achieved through vaccination. The data were obtained by two independent research teams using catumaxomab in malignant ascites and gastric cancer, respectively. The results were recently presented at the annual meeting of the American Society of Clinical Oncology (ASCO).

6 Jun 2011

Waters introduces SYNAPT G2-S at 59th ASMS Conference on Mass Spectrometry

Waters Corporation today introduced the SYNAPT® G2-S High Definition Mass Spectrometer, representing a significant step forward in performance for High Definition Mass Spectrometry. The SYNAPT G2-S incorporates both high-sensitivity Waters StepWave™ ion transfer optics and Triwave® ion mobility technologies along with a suite of new informatics tools to take qualitative and quantitative high resolution performance to a new level.

6 Jun 2011

Constellation raises $15M in Series B extension financing

Constellation Pharmaceuticals, Inc., a leading biopharmaceutical company in the field of epigenetics, today announced that it has raised $15 million in a Series B extension financing. All major current investors participated in the round, including Third Rock Ventures, The Column Group, Venrock Associates, SR One and Altitude Life Science Ventures.

6 Jun 2011

Biopharmaceutical News and Research

ViroPharma receives European Centralized Marketing Authorization for Cinryze for treatment of HAE

Saint-Gobain introduces new C-Flex ULTRA TPE pump tubing for biopharmaceutical applications

immatics initiates IMA901 Phase III trial in renal cell carcinoma

Sangart commences MP4OX Phase 2b study in acute traumatic injury

Morimatsu acquires Pharmadule

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

Saint-Gobain Performance Plastics redesigns standard laboratory carboy

Trimeris, Synageva enter definitive merger agreement

Circassia announces ToleroMune vaccine phase II trial results against cat allergy

Hanwha, Merck partner to develop and commercialize HD203

Ambit Biosciences raises $30 million through Series D-2 equity financing

Repligen total revenue increases 30% to $27,291,000 for fiscal year 2011

Grifols officially merges with Talecris Biotherapeutics

Shire Canada receives expanded indication for MEZAVANT for treatment of ulcerative colitis

VentiRx presents VTX-2337 Phase 1 trial results against advanced solid tumors at ASCO 2011

Crucell, GSK and PATH MVI partner to develop second-generation vaccine against malaria

PATH malaria vaccine initiative to collaborate with GSK and Crucell in development of 2nd-generation malaria vaccine

Trifunctional antibody Catumaxomab triggers vaccination effect against cancer

Waters introduces SYNAPT G2-S at 59th ASMS Conference on Mass Spectrometry

Constellation raises $15M in Series B extension financing

Event guide: The 5th mRNA-Based Therapeutics Summit Europe eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News